Immunome (IMNM) closed at $18.21 on October 30, 2026, down 0.4% from the previous close, on volume of 1,160,708 shares (30-day average 1,454,671).
Data as of October 30, 2026.
30-Oct-2026
Business Wire (Fri, 30-Oct 7:30 AM ET)
Immunome Advances Varegacestat Capsule Study, Signaling Steady R&D Progress
TipRanks (Thu, 29-Oct 12:31 PM ET)
Wedbush Keeps Their Buy Rating on Immunome (IMNM)
TipRanks (Tue, 27-Oct 11:56 AM ET)
TipRanks (Tue, 27-Oct 7:27 AM ET)
Analysts’ Top Healthcare Picks: Cardinal Health (CAH), Immunome (IMNM)
TipRanks (Tue, 27-Oct 5:00 AM ET)
Market Chameleon (Mon, 26-Oct 5:19 AM ET)
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Business Wire (Mon, 26-Oct 7:00 AM ET)
Immunome issues inducement grants to 10 new hires with $20.89 option strike
Market Chameleon (Wed, 7-Oct 7:57 AM ET)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Tue, 6-Oct 4:02 PM ET)
Business Wire (Wed, 30-Sep 7:45 AM ET)
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Immunome trades on the NASDAQ stock market under the symbol IMNM.
As of October 30, 2026, IMNM stock price declined to $18.21 with 1,160,708 million shares trading.
IMNM has a beta of 1.56, meaning it tends to be more sensitive to market movements. IMNM has a correlation of 0.13 to the broad based SPY ETF.
IMNM has a market cap of $2.15 billion. This is considered a Mid Cap stock.
Last quarter Immunome reported $0 in Revenue and -$.65 earnings per share. This fell short of revenue expectation by $-533,336 and missed earnings estimates by -$.14.
In the last 3 years, IMNM traded as high as $30.96 and as low as $5.15.
The top ETF exchange traded funds that IMNM belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
IMNM has outperformed the market in the last year with a price return of +14.0% while the SPY ETF gained +12.3%. However, in the short term, IMNM had mixed performance relative to the market. It has underperformed in the last 3 months, returning -21.1% vs +2.1% return in SPY. But in the last 2 weeks, IMNM shares have fared better than the market returning +10.6% compared to SPY -1.0%.
IMNM support price is $17.60 and resistance is $18.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNM shares will trade within this expected range on the day.